ANIK Anika Therapeutics (ANIK) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000898437
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
68
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about ANIK
Insiders, 180 days
+$114.4K net bought
2 buyers
Planned sales (Form 144), 90 days
$355.3K
1 notice
Anika Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Anika Therapeutics, Inc. insiders bought a net $114.4K of stock across 12 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 3, 2026.
- The trade is 1.9% of the 54,015 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fischetti Gary P bought about $20.3K of ANIK on Aug 4, 2026; 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 1.9% of the 53,015 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fischetti Gary P bought about $20.7K of ANIK on Aug 3, 2026; 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.1% of the 54,871 shares held after it.
- 1 other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HENNEMAN JOHN B III bought about $73.3K of ANIK on May 1, 2026; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.7% of the 36,163 shares held after it.
- 1 other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Griffin Stephen D. bought about $149.9K of ANIK on Apr 30, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 68 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 14, 2022.
- The trade is 15.2% of the 9,867 shares held after it.
- No other insider bought within 30 days.
- 68 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, General Counsel, Corp Sec Colleran David bought about $32.1K of ANIK on May 11, 2022; 68 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$114.4K over 180 days
+$41.1K over 90 days
more than 73% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
68 funds bought in last quarter
more than 52% of Medical Devices
Revenue
-5.9% year over year
below 84% of Medical Devices
Margin
-9.6% net margin
more than 57% of Medical Devices
Buybacks
$9.5M repurchased, FY to 2026-06-30
below 63% of Medical Devices
Short interest
3.2% of the float short (float per yahoo 2026-10-27) · 3.4 days to cover · settled 2026-10-15
below 55% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ANIK
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+121.2%12M
Insider buyForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ANIK: institutional holders (13F)
13F holdings, latest reported quarter
1,449,671 sh
$21.2M
1,435,130 sh
$21.0M
614,320 sh
$9.0M
572,113 sh
$8.4M
559,846 sh
$8.2M
Congress trades in ANIK
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ANIK planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Jellison William R
Filed 2026-08-07
$355.3K
ANIK mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$77.7K position · as of 2026-05-31
0.4%
MFS Blended Research Small Cap Equity Fund
$699.9K position · as of 2026-05-31
0.2%
MFS Blended Research Small Cap Equity Portfolio
$177.6K position · as of 2026-06-30
0.2%
Royce Quant Small-Cap Quality Value ETF
$53.4K position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$256.0K position · as of 2026-06-30
0.2%
NVIT Small Cap Value Fund
$305.5K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
12 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 3
0 active
10
Not applicable
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Darling
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2019
$288.8K
-$7.1M
n/a
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. This filer reported no return figures.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $114.4K bought by insiders over 180 days, 68 funds added last quarter, $355.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ANIK financials
Revenue growth
-5.9%
XBRL, annual
Net margin
-9.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$120.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ANIK
| FY Dec 2025 | $112.8M |
| FY Dec 2024 | $119.9M |
| FY Dec 2023 | $166.7M |
| FY Dec 2022 | $156.2M |
| FY Dec 2021 | $147.8M |
| Jun 2026 | $32.6M |
| Mar 2026 | $29.6M |
| Dec 2025 | $30.6M |
| Sep 2025 | $27.8M |
| Jun 2025 | $28.2M |
| Mar 2025 | $26.2M |
| Dec 2024 | -$1.3M |
| Sep 2024 | $38.8M |
At each fiscal year end
Single quarter
Net margin, TTM
-3.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ANIK
| FY Dec 2025 | -9.8% |
| FY Dec 2024 | -46.7% |
| FY Dec 2023 | -49.8% |
| FY Dec 2022 | -9.6% |
| FY Dec 2021 | +2.7% |
| Jun 2026 | +10.1% |
| Mar 2026 | -17.1% |
| Dec 2025 | +0.6% |
| Sep 2025 | -8.4% |
| Jun 2025 | -14.1% |
| Mar 2025 | -18.6% |
| Dec 2024 | n/a |
| Sep 2024 | -77.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$562.0K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ANIK
| FY Dec 2025 | $4.4M |
| FY Dec 2024 | -$2.3M |
| FY Dec 2023 | -$7.2M |
| FY Dec 2022 | -$3.1M |
| FY Dec 2021 | $3.3M |
| Jun 2026 | -$2.1M |
| Mar 2026 | -$6.3M |
| Dec 2025 | $4.0M |
| Sep 2025 | $5.0M |
| Jun 2025 | -$1.7M |
| Mar 2025 | -$3.0M |
| Dec 2024 | $275.0K |
| Sep 2024 | $3.8M |
At each fiscal year end
Single quarter
Debt to equity
0.18x
long-term debt only, 2020-09-30 (69 months older than the period end); equity 2026-06-30
Debt to equity ANIK
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.16x |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | 0.09x |
| FY Dec 2021 | 0.09x |
| Jun 2026 | 0.18x |
| Mar 2026 | 0.19x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.17x |
| Jun 2025 | 0.17x |
| Mar 2025 | 0.17x |
| Dec 2024 | 0.16x |
| Sep 2024 | 0.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.24x
TTM operating cash flow over long-term debt only, 2020-09-30 (69 months older than the period end)
Cash flow to debt ANIK
| FY Dec 2025 | 0.45x |
| FY Dec 2024 | 0.22x |
| FY Dec 2023 | -0.07x |
| FY Dec 2022 | 0.18x |
| FY Dec 2021 | 0.34x |
| Jun 2026 | 0.24x |
| Mar 2026 | 0.26x |
| Dec 2025 | 0.45x |
| Sep 2025 | 0.33x |
| Jun 2025 | 0.25x |
| Mar 2025 | 0.22x |
| Dec 2024 | 0.22x |
| Sep 2024 | 0.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-2.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ANIK
| FY Dec 2025 | -7.4% |
| FY Dec 2024 | -30.6% |
| FY Dec 2023 | -33.3% |
| FY Dec 2022 | -5.2% |
| FY Dec 2021 | +1.4% |
| Jun 2026 | -2.7% |
| Mar 2026 | -7.9% |
| Dec 2025 | -7.4% |
| Sep 2025 | -20.0% |
| Jun 2025 | -33.7% |
| Mar 2025 | -31.6% |
| Dec 2024 | -30.6% |
| Sep 2024 | -43.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-2.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ANIK
| FY Dec 2025 | -5.6% |
| FY Dec 2024 | -23.7% |
| FY Dec 2023 | -26.8% |
| FY Dec 2022 | -4.3% |
| FY Dec 2021 | +1.1% |
| Jun 2026 | -2.1% |
| Mar 2026 | -6.0% |
| Dec 2025 | -5.6% |
| Sep 2025 | -15.5% |
| Jun 2025 | -26.8% |
| Mar 2025 | -24.8% |
| Dec 2024 | -23.7% |
| Sep 2024 | -35.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ANIK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +0.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-3.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ANIK
| FY Dec 2025 | -6.4% |
| FY Dec 2024 | -2.4% |
| FY Dec 2023 | +0.3% |
| FY Dec 2022 | +1.1% |
| FY Dec 2021 | +0.8% |
| Jun 2026 | -3.1% |
| Mar 2026 | -7.4% |
| Dec 2025 | -6.4% |
| Sep 2025 | -6.6% |
| Jun 2025 | -4.5% |
| Mar 2025 | -3.4% |
| Dec 2024 | -2.4% |
| Sep 2024 | +8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ANIK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 123.55x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$272.3M
market value at close 2026-10-27 on 2026-07-24 shares, plus long-term debt only, 2020-09-30 (69 months older than the period end), minus cash 2026-06-30
Enterprise value ANIK
| FY Dec 2025 | $106.1M |
| FY Dec 2024 | $210.4M |
| FY Dec 2023 | $288.0M |
| FY Dec 2022 | $371.1M |
| FY Dec 2021 | $447.9M |
| Jun 2026 | $181.2M |
| Mar 2026 | $178.3M |
| Dec 2025 | $106.1M |
| Sep 2025 | $102.5M |
| Jun 2025 | $123.6M |
| Mar 2025 | $184.7M |
| Dec 2024 | $210.4M |
| Sep 2024 | $328.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield ANIK
| FY Dec 2025 | +3.1% |
| FY Dec 2024 | -1.0% |
| FY Dec 2023 | -2.2% |
| FY Dec 2022 | -0.7% |
| FY Dec 2021 | +0.6% |
| Jun 2026 | +0.3% |
| Mar 2026 | +0.5% |
| Dec 2025 | +3.1% |
| Sep 2025 | +0.5% |
| Jun 2025 | -0.4% |
| Mar 2025 | -1.6% |
| Dec 2024 | -1.0% |
| Sep 2024 | -0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ANIK
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $166.7M | $156.2M |
| Gross profit | $63.8M | $76.0M | $82.5M | $73.2M |
| Operating income | -$11.1M | -$5.1M | $844.0K | $3.7M |
| Net income | -$11.0M | -$56.0M | -$83.0M | -$15.0M |
| EPS (diluted) | -0.76 | -3.83 | -5.64 | -1.02 |
| Operating cash flow | $11.2M | $5.4M | -$1.8M | $4.4M |
| Cash | $57.5M | $55.6M | $68.7M | $86.3M |
| Buybacks | $9.5M | $10.9M | $5.0M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
ANIK Stock Sonar score 6/7 axes
Find similar shapesCompareANIK ranks highest on insider conviction (73rd percentile) and financial health (66th), and lowest on growth (16th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ANIK filings, in plain words
Are Anika Therapeutics insiders buying or selling ANIK?
In the 180 days to 2026-10-28, Anika Therapeutics insiders were net buyers, a net $114.4K across purchases and sales reported on Form 4, by 2 buyers.
Are there planned insider sales of ANIK?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $355.3K of stock; the latest, by Jellison William R, was filed 2026-08-07.
Read the full summary
In the 180 days to 2026-10-28, Anika Therapeutics insiders were net buyers of ANIK, a net $114.4K across purchases and sales reported on Form 4 by 2 buyers. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $355.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
